A study published on 16 October 2026 in Nature Medicine reports outcomes for 8,127 women in the UK who started GLP-1 treatment, almost all of them on tirzepatide, through a structured online programme. Average weight loss at six months was 16.1 kg, or 15.5% of starting weight. It is one of the largest prospective looks … Read more
When the UK list price of tirzepatide (sold as Mounjaro) rose by up to 170% in September 2025, people paying privately for weight-loss injections moved quickly toward the cheaper alternative. A study of more than one million self-paying adults at a single UK online provider, published on 14 October in Diabetes, Obesity and Metabolism, found … Read more
The FDA issued a further round of warning letters on 8 June 2026, including to Altru Telehealth, Medica Weight Loss and FITISH, continuing the enforcement line it opened in September 2025 and widened in March 2026. Sources: Altru Telehealth · Medica Weight Loss · FITISH
The FDA issued warning letters to 30 telehealth companies over false or misleading claims made about compounded GLP-1 products sold on their websites. It was the second wave of letters aimed at telehealth firms since the agency opened a broader campaign against misleading direct-to-consumer drug advertising in September 2025, and the largest single action against … Read more